Abstract
CCAAT/enhancer-binding proteins (C/EBPs) are a family of highly conserved transcription factors that have important roles in normal myelopoiesis as well as associated with myeloid disorders. The chronic myelogenous leukemia (CML) cell lines, KCL22 and K562, express exceptionally low levels of endogenous C/EBPs and provide a good model to test the effects of C/EBPs on myeloid differentiation. To explore the possibility that C/EBPδ can promote differentiation in BCR-ABL-positive cells, we generated stable KCL22 and K562 clones that expressed an inducible C/EBPδ gene. C/EBPδ expression resulted in G0/G1 proliferative arrest and a moderate increase in apoptosis of the KCL22 and the K562 cells. Within 4 days of inducing expression of C/EBPδ, myeloid differentiation of the CML blast cells occurred as shown by morphologic changes and induction of secondary granule-specific genes. We also showed that during granulocytic differentiation of KCL22 cells, the C/EBPδ protein was detected in immunocomplexes with both Rb and E2F1. Furthermore, expression of C/EBPδ was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27Kip1 in both the KCL22 and K562 cell lines. These results show that expression of C/EBPδ in BCR-ABL-positive leukemic cells in blast crisis is sufficient for neutrophil differentiation and point to the therapeutic potential of ectopic induction of C/EBPδ in the acute phase of CML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A and Cline M . (1991). J. Clin. Invest., 87, 2042–2047.
Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, Ben-Neriah Y and Ben-Yehuda D . (1999). Blood, 94, 2452–2460.
Billiard J, Umayahara Y, Wiren K, Centrella M, McCarthy TL and Rotwein P . (2001). J. Biol. Chem., 276, 15354–15361.
Breed DR, Margraf LR, Alcorn JL and Mendelson CR . (1997). Endocrinology, 138, 5527–5534.
Cantwell CA, Sterneck E and Johnson PF . (1998). Mol. Cell. Biol., 18, 2108–2117.
Cao Z, Umek RM and McKnight SL . (1991). Genes Dev., 5, 1538–1552.
Chen PL, Riley DJ, Chen Y and Lee WH . (1996). Genes Dev., 10, 2794–2804.
D'Alo' F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P, Nerlov C and Tenen DG . (2003). Blood, 102, 3163–3171.
Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K and Oberg F . (2002). Blood, 99, 2199–2206.
Duprez E, Wagner K, Koch H and Tenen DG . (2003). EMBO J., 22, 5806–5816.
Friedman AD . (2002). Oncogene, 21, 3377–3390.
Gery S, Gombart AF, Fung YK and Koeffler HP . (2004). Blood, 103, 828–835.
Gheorghiu I, Deschenes C, Blais M, Boudreau F, Rivard N and Asselin C . (2001). J. Biol. Chem., 276, 44331–44337.
Hoffman B, Amanullah A, Shafarenko M and Liebermann DA . (2002). Oncogene, 21, 3414–3421.
Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W and Koeffler HP . (2002). Blood, 100, 3553–3560.
Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, Ishikawa T, Yazaki Y and Hirai H . (2000). Blood, 95, 1144–1150.
Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR and Tenen DG . (2001). Mol Cell Biol., 21, 3789–3806.
Jones LC, Lin ML, Chen SS, Krug U, Hofmann WK, Lee S, Lee YH and Koeffler HP . (2002). Blood, 99, 2032–2036.
Kubota T, Hirama T, Verbeek W, Kawano S, Chih DY, Chumakov AM, Taguchi H and Koeffler HP . (2001). Leuk. Res., 25, 981–995.
Mori N, Morosetti R, Lee S, Spira S, Ben-Yehuda D, Schiller G, Landolfi R, Mizoguchi H and Koeffler HP . (1997). Blood, 90, 2010–2014.
Morosetti R, Park DJ, Chumakov AM, Grillier I, Shiohara M, Gombart AF, Nakamaki T, Weinberg K and Koeffler HP . (1997). Blood, 90, 2591–2600.
O'Rourke JP, Newbound GC, Hutt JA and DeWille J . (1999). J. Biol. Chem., 274, 16582–16589.
Park DJ, Chumakov AM, Vuong PT, Chih DY, Gombart AF, Miller Jr WH and Koeffler HP . (1999). J. Clin. Invest., 103, 1399–1408.
Perez-Roger I, Solomon DL, Sewing A and Land H . (1997). Oncogene, 14, 2373–2381.
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA and Calabretta B . (2002). Nat. Genet., 30, 48–58.
Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT and Tenen DG . (1998). Mol. Cell. Biol., 18, 4301–4314.
Ramji DP and Foka P . (2002). Biochem. J., 365, 561–575.
Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M and Warmuth M . (2003). Blood, 101, 655–663.
Scott LM, Civin CI, Rorth P and Friedman AD . (1992). Blood, 80, 1725–1735.
Slomiany BA, D'Arigo KL, Kelly MM and Kurtz DT . (2000). Mol. Cell. Biol., 20, 5986–5997.
Tanaka T, Yoshida N, Kishimoto T and Akira S . (1997). EMBO J., 16, 7432–7443.
Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF and Koeffler PH . (2003). J. Biol. Chem., 278, 52651–52659.
Timchenko NA, Wilde M and Darlington GJ . (1999). Mol. Cell. Biol., 19, 2936–2945.
Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U, Fermin AC, Heaney A, Miller CW and Koeffler HP . (2002). Leuk. Res., 26, 451–457.
Verbeek W, Gombart AF, Chumakov AM, Muller C, Friedman AD and Koeffler HP . (1999). Blood, 93, 3327–3337.
Wang QF and Friedman AD . (2002). Blood, 99, 2776–2785.
Yamanaka R, Lekstrom-Himes J, Barlow C, Wynshaw-Boris A and Xanthopoulos KG . (1998). Int. J. Mol. Med., 1, 213–221.
Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP and Sonenshein GE . (2001). Oncogene, 20, 1688–1702.
Acknowledgements
This work was supported in part by National Institutes of Health grants as well as the Ronald Havner, Parker Hughes, and the Cindy and Alan Horn funds. HPK is a member of the Jonsson Comprehensive Cancer Center and the Molecular Biology Institute (UCLA) and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gery, S., Tanosaki, S., Hofmann, WK. et al. C/EBPδ expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 24, 1589–1597 (2005). https://doi.org/10.1038/sj.onc.1208393
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208393
Keywords
This article is cited by
-
A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer
Nature Biotechnology (2021)
-
C/EBPδ protects from radiation-induced intestinal injury and sepsis by suppression of inflammatory and nitrosative stress
Scientific Reports (2019)
-
Regulation of Clock Genes by Adrenergic Receptor Signaling in Osteoblasts
Neurochemical Research (2018)
-
Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia
Cell Death & Disease (2017)
-
Identification of potential crucial gene network related to seasonal allergic rhinitis using microarray data
European Archives of Oto-Rhino-Laryngology (2017)